Investors Not Impressed With Valeant's New Bid For Allergan

May 28 2014, 11:06am CDT | by

For two weeks, Valeant Pharmaceuticals has been promising to bolster its hostile bid for Allergan to win the widely watched takeover battle. But investors do not seem to be impressed with Valeant’s enhanced $49 billion offer for the maker of Botox.

Valeant increased on Wednesday morning the cash that the company is offering Allergan shareholders by $10 per share to $58.30. Valeant continued to offer the same 0.83 of a Valeant share and added a contingent value right sweetener around Allergan’s experimental vision-loss drug that Valeant claims could result in payments to Allergan shareholders worth as much as $25 a share.

In the tax-driven deals that companies like Valeant have pursued aggressively in recent years, shares of both the acquirer and seller have tended to increase when the deals are announced. Investors, however, sold shares of both Valeant and Allergan on Wednesday. In morning trading, shares of Valeant fell by 2.2% and shares of Allergan dropped by 4.4% to $157.77. Wall Street analysts from Credit Suisse and Wells Fargo said that the new Valeant offer could not be good enough. “We hoped for something more imaginative, like substantially altering the share of cash and stock Valeant will use or a more substantial increase in the value offer,” wrote Aaron “Ronny” Gal, an analyst at Bernstein Research. “The Valeant offer is rather disappointing. It does not really alter the fundamental value of the offer.”

Like a hedge fund manager promoting a short position, Allergan came out swinging against Valeant Pharmaceuticals on Tuesday, questioning whether Valeant’s low tax rate was sustainable and raising other issues surrounding Valeant’s debt-fueled acquisition strategy and accounting. The point was to undermine the appeal to Allergan shareholders of Valeant’s stock, which Valeant is using as currency for its proposed deal. Allergan’s board said on Wednesday that it will review the new Valeant proposal, but Allergan’s board and its CEO, David Pyott, have made it pretty clear they want to keep Allergan an independent company.

During a long presentation on Wednesday to promote his new offer, Valeant CEO Michael Pearson said many of Allergan’s assertion against his acquisition-driven business model were incorrect. “It was a little insulting to be called a Tyco but I guess time will tell,” Pearson said. “This industry the R&D productivity has been very very low, so how all companies grow in this industry is through making really good acquisitions and growing those acquisitions after they make them.”

Pearson, who is working with hedge fund billionaire William Ackman in this takeover effort, said he fully expects Valeant will be successful in its attempt to purchase Botox-maker Allergan. In a sign that he means business, Valeant also announced on Wednesday that it will sell several injectable treatments for facial wrinkles to Nestle for $1.4 billion. At the same time, Pearson was careful to say that he would not be putting together an all-cash deal for Allergan or bid against himself. “We are not going to keep offering against ourselves,” Pearson said. “We are still willing to sit down with management and the board to negotiate a deal, but we are not going to continue increasing our offering until we have that chance to sit down.”

 
 

Don't miss ...

 

<a href="/latest_stories/all/all/30" rel="author">Forbes</a>
Forbes is among the most trusted resources for the world's business and investment leaders, providing them the uncompromising commentary, concise analysis, relevant tools and real-time reporting they need to succeed at work, profit from investing and have fun with the rewards of winning.

 

blog comments powered by Disqus

Latest stories

SJVNL signs pact with Nepal for hydro-power plant
Kathmandu, Nov 27 (IANS) Indian public sector company Satluj Jal Vidyut Nigam Ltd. (SJVNL) has signed a project development agreement with the Nepal government for executing the 900 MW Arun-III Hydro Electric Project in eastern Nepal, officials said Thursday.
 
 
'I saw humans on Mars in 1979': Ex-NASA employee
New York, Nov 27 (IANS) A woman claiming to be a former NASA employee has stated that while watching some footage, she saw two humans walking on the Red Planet towards the Viking Mars lander in 1979.
 
 
Mammoth cloning reality soon?
New York, Nov 27 (IANS) With the discovery of the best-preserved specimen of a mammoth found so far, cloning of the woolly animal is closer to becoming a reality, scientists report.
 
 
Saarc energy accord signed
Kathmandu, Nov 27 (IANS) The foreign ministers of Saarc member states have signed the Saarc Framework Agreement for Energy Cooperation (Electricity).
 
 
 

Latest from the Network

13 civilians killed by Ukrainian forces: Separatists
Moscow, Nov 27 (IANS/EFE) At least 13 civilians were killed in recent shelling by Ukrainian artillery in the eastern city of Donetsk controlled by pro-Russian separatists, the rebel command announced Thursday. A...
Read more on Politics Balla
 
Zambian police gear up for presidential election
Lusaka, Nov 27 (IANS) Police in Zambia have stepped up measures to ensure peace ahead of a presidential election scheduled for Jan 20, a top official said Thursday. Stella Libongani, the inspector general of Zambia...
Read more on Politics Balla
 
Hong Kong students threaten to occupy government buildings
Hong Kong, Nov 27 (IANS/EFE) Students participating in the pro-democracy demonstrations in Hong Kong threatened Thursday to attack government buildings following a night of clashes that occurred just hours after the...
Read more on Politics Balla
 
Cricketers who died of injuries on the field
Sydney, Nov 27 (IANS) Phil Hughes Thursday joined the list of cricket players who died of the injuries sustained while playing the game. Here's a list of the players who died after getting injured while playing: 1....
Read more on Sport Balla
 
Syrian army claims killing 50 rebels near Damascus
Damascus, Nov 27 (IANS/EFE) The Syrian Army announced Thursday that it had killed at least 50 "terrorists", as it describes anti-government insurgents, in an ambush outside Damascus, the state-run Sana news agency said...
Read more on Politics Balla
 
Danish parliament speaker to head UN General Assembly
Copenhagen, Nov 27 (IANS) Danish parliament Speaker Mogens Lykketoft will become the next president of the UN General Assembly in September 2015 replacing current president, Uganda's Sam Kutesa, media reported Thursday...
Read more on Politics Balla
 
Cricket community rallies behind bowler Abbott
London, Nov 27 (IANS) The cricket community has lent his support to bowler Sean Abbott, left distraught after his bouncer hit Phillip Hughes on the head, leading to his death Thursday. The young pace bowler delivered...
Read more on Sport Balla
 
Modi, Sharif shake hands, chat at Saarc closing event
Kathmandu, Nov 27 (IANS) In an ice-breaking moment, Indian Prime Minister Narendra Modi shook hands with his Pakistani counterpart Nawaz Sharif, laughed and even slapped him laughingly on the arm while sharing a light...
Read more on Politics Balla
 
'I saw humans on Mars in 1979': Ex-NASA employee
New York, Nov 27 (IANS) A woman claiming to be a former NASA employee has stated that while watching some footage, she saw two humans walking on the Red Planet towards the Viking Mars lander in 1979. Calling herself "...
Read more on Business Balla
 
Cameron anxiously awaits 'Avatar' sequel release
Los Angeles, Nov 27 (IANS) If one goes by "Avatar" filmmaker James Cameron's words, the planned sequel of the 2009 epic sci-fi movie will leave the audience mesmerised. "You will s--t yourself with your mouth wide...
Read more on Celebrity Balla
 
 
Investors Not Impressed With Valeant's New Bid For Allergan - Business Balla
 

Investors Not Impressed With Valeant's New Bid For Allergan

May 28 2014, 11:06am CDT | by

For two weeks, Valeant Pharmaceuticals has been promising to bolster its hostile bid for Allergan to win the widely watched takeover battle. But investors do not seem to be impressed with Valeant’s enhanced $49 billion offer for the maker of Botox.

Valeant increased on Wednesday morning the cash that the company is offering Allergan shareholders by $10 per share to $58.30. Valeant continued to offer the same 0.83 of a Valeant share and added a contingent value right sweetener around Allergan’s experimental vision-loss drug that Valeant claims could result in payments to Allergan shareholders worth as much as $25 a share.

In the tax-driven deals that companies like Valeant have pursued aggressively in recent years, shares of both the acquirer and seller have tended to increase when the deals are announced. Investors, however, sold shares of both Valeant and Allergan on Wednesday. In morning trading, shares of Valeant fell by 2.2% and shares of Allergan dropped by 4.4% to $157.77. Wall Street analysts from Credit Suisse and Wells Fargo said that the new Valeant offer could not be good enough. “We hoped for something more imaginative, like substantially altering the share of cash and stock Valeant will use or a more substantial increase in the value offer,” wrote Aaron “Ronny” Gal, an analyst at Bernstein Research. “The Valeant offer is rather disappointing. It does not really alter the fundamental value of the offer.”

Like a hedge fund manager promoting a short position, Allergan came out swinging against Valeant Pharmaceuticals on Tuesday, questioning whether Valeant’s low tax rate was sustainable and raising other issues surrounding Valeant’s debt-fueled acquisition strategy and accounting. The point was to undermine the appeal to Allergan shareholders of Valeant’s stock, which Valeant is using as currency for its proposed deal. Allergan’s board said on Wednesday that it will review the new Valeant proposal, but Allergan’s board and its CEO, David Pyott, have made it pretty clear they want to keep Allergan an independent company.

During a long presentation on Wednesday to promote his new offer, Valeant CEO Michael Pearson said many of Allergan’s assertion against his acquisition-driven business model were incorrect. “It was a little insulting to be called a Tyco but I guess time will tell,” Pearson said. “This industry the R&D productivity has been very very low, so how all companies grow in this industry is through making really good acquisitions and growing those acquisitions after they make them.”

Pearson, who is working with hedge fund billionaire William Ackman in this takeover effort, said he fully expects Valeant will be successful in its attempt to purchase Botox-maker Allergan. In a sign that he means business, Valeant also announced on Wednesday that it will sell several injectable treatments for facial wrinkles to Nestle for $1.4 billion. At the same time, Pearson was careful to say that he would not be putting together an all-cash deal for Allergan or bid against himself. “We are not going to keep offering against ourselves,” Pearson said. “We are still willing to sit down with management and the board to negotiate a deal, but we are not going to continue increasing our offering until we have that chance to sit down.”

 
 

Don't miss ...

 

<a href="/latest_stories/all/all/30" rel="author">Forbes</a>
Forbes is among the most trusted resources for the world's business and investment leaders, providing them the uncompromising commentary, concise analysis, relevant tools and real-time reporting they need to succeed at work, profit from investing and have fun with the rewards of winning.

 

blog comments powered by Disqus

Latest stories

SJVNL signs pact with Nepal for hydro-power plant
Kathmandu, Nov 27 (IANS) Indian public sector company Satluj Jal Vidyut Nigam Ltd. (SJVNL) has signed a project development agreement with the Nepal government for executing the 900 MW Arun-III Hydro Electric Project in eastern Nepal, officials said Thursday.
 
 
'I saw humans on Mars in 1979': Ex-NASA employee
New York, Nov 27 (IANS) A woman claiming to be a former NASA employee has stated that while watching some footage, she saw two humans walking on the Red Planet towards the Viking Mars lander in 1979.
 
 
Mammoth cloning reality soon?
New York, Nov 27 (IANS) With the discovery of the best-preserved specimen of a mammoth found so far, cloning of the woolly animal is closer to becoming a reality, scientists report.
 
 
Saarc energy accord signed
Kathmandu, Nov 27 (IANS) The foreign ministers of Saarc member states have signed the Saarc Framework Agreement for Energy Cooperation (Electricity).
 
 
 

Latest from the Network

13 civilians killed by Ukrainian forces: Separatists
Moscow, Nov 27 (IANS/EFE) At least 13 civilians were killed in recent shelling by Ukrainian artillery in the eastern city of Donetsk controlled by pro-Russian separatists, the rebel command announced Thursday. A...
Read more on Politics Balla
 
Zambian police gear up for presidential election
Lusaka, Nov 27 (IANS) Police in Zambia have stepped up measures to ensure peace ahead of a presidential election scheduled for Jan 20, a top official said Thursday. Stella Libongani, the inspector general of Zambia...
Read more on Politics Balla
 
Hong Kong students threaten to occupy government buildings
Hong Kong, Nov 27 (IANS/EFE) Students participating in the pro-democracy demonstrations in Hong Kong threatened Thursday to attack government buildings following a night of clashes that occurred just hours after the...
Read more on Politics Balla
 
Cricketers who died of injuries on the field
Sydney, Nov 27 (IANS) Phil Hughes Thursday joined the list of cricket players who died of the injuries sustained while playing the game. Here's a list of the players who died after getting injured while playing: 1....
Read more on Sport Balla
 
Syrian army claims killing 50 rebels near Damascus
Damascus, Nov 27 (IANS/EFE) The Syrian Army announced Thursday that it had killed at least 50 "terrorists", as it describes anti-government insurgents, in an ambush outside Damascus, the state-run Sana news agency said...
Read more on Politics Balla
 
Danish parliament speaker to head UN General Assembly
Copenhagen, Nov 27 (IANS) Danish parliament Speaker Mogens Lykketoft will become the next president of the UN General Assembly in September 2015 replacing current president, Uganda's Sam Kutesa, media reported Thursday...
Read more on Politics Balla
 
Cricket community rallies behind bowler Abbott
London, Nov 27 (IANS) The cricket community has lent his support to bowler Sean Abbott, left distraught after his bouncer hit Phillip Hughes on the head, leading to his death Thursday. The young pace bowler delivered...
Read more on Sport Balla
 
Modi, Sharif shake hands, chat at Saarc closing event
Kathmandu, Nov 27 (IANS) In an ice-breaking moment, Indian Prime Minister Narendra Modi shook hands with his Pakistani counterpart Nawaz Sharif, laughed and even slapped him laughingly on the arm while sharing a light...
Read more on Politics Balla
 
'I saw humans on Mars in 1979': Ex-NASA employee
New York, Nov 27 (IANS) A woman claiming to be a former NASA employee has stated that while watching some footage, she saw two humans walking on the Red Planet towards the Viking Mars lander in 1979. Calling herself "...
Read more on Business Balla
 
Cameron anxiously awaits 'Avatar' sequel release
Los Angeles, Nov 27 (IANS) If one goes by "Avatar" filmmaker James Cameron's words, the planned sequel of the 2009 epic sci-fi movie will leave the audience mesmerised. "You will s--t yourself with your mouth wide...
Read more on Celebrity Balla